Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet Kluger, Omid Hamid, Eric Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf FinckensteinMadan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod Sarnaik
Dive into the research topics of 'Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study'. Together they form a unique fingerprint.